

VECTOR BIOSCIENCE CAMBRIDGE LTD

Registered Number
13564111
(England and Wales)

Unaudited Financial Statements for the Period ended
31 August 2022

VECTOR BIOSCIENCE CAMBRIDGE LTD
Company Information
for the period from 13 August 2021 to 31 August 2022

Directors	BRINKSMA, Jogchum
	FAIREN-JIMENEZ, David, Dr
	GALLEGO SEGRELLES, Lluna

Registered Address	20-22 Wenlock Road
	London
	N1 7GU

Registered Number	13564111 (England and Wales)
--------------------------	------------------------------

VECTOR BIOSCIENCE CAMBRIDGE LTD

Balance Sheet as at 31 August 2022

	Notes	2022
		£
Current assets		
Debtors		114
Cash at bank and on hand		368
		<hr/> 482
Creditors amounts falling due within one year		(10,000)
		<hr/>
Net current assets (liabilities)		(9,518)
Total assets less current liabilities		<hr/> (9,518)
Net assets		<hr/> (9,518)
Capital and reserves		
Called up share capital		100
Profit and loss account		(9,618)
		<hr/>
Shareholders' funds		<hr/> (9,518)

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company's profit and loss account.

The financial statements were approved and authorised for issue by the Board of Directors on 6 February 2023, and are signed on its behalf by:

GALLEGO SEGRELLES, Lluna
Director
Registered Company No. 13564111

VECTOR BIOSCIENCE CAMBRIDGE LTD

Notes to the Financial Statements for the period ended 31 August 2022

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Compliance with applicable reporting framework

The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.

3. Principal activities

The principal activity of the company is that of tailoring the best nanomaterials for drug delivery applications.

4. Accounting policies

Revenue recognition policy

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Foreign currency translation and operations policy

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

5. Employee information

2022

Average number of employees during the year

0

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.